Amycretin, a new weight-loss treatment from Novo Nordisk, combines two hunger hormones, helping participants lose nearly ...

Top executives ignored warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, ...

One in eight Americans use GLP-1 weight-loss drugs, but are they getting the real thing? Novo Nordisk's dramatic exit from a popular platform reveals the hidden risks of online prescriptions.

Novo Nordisk said it will stop selling Wegovy on Hims & Hers, claiming the telehealth company sold knockoff versions of the weight-loss drug.

Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently approved medicine, Zepbound, but didn’t cleanly surpass it in late ...

An experimental weight-loss pill helped people drop 13% of their body weight in a three-month period. The results from early clinical trials were presented by Novo Nordisk this week.

Novo Nordisk's pipeline, especially the oral GLP-1 and Alzheimer’s trial, offers significant long-term upside. Click here to ...

Novo Nordisk's U.S.-listed shares fell close to 6% Monday after the drugmaker revealed the latest results for a new weight-loss treatment.

The Danish pharmaceutical said it was ending the partnership because Hims is selling and promoting a cheaper copycat of its ...

The stock of Novo Nordisk (NVO-1.00%) has been a hot buy over the past few years (up 270% in three years), largely due to the success of its diabetes and weight loss drugs.. Even if you aren't ...

The company behind the weight loss sensation that transformed bodies and bank accounts across America just showed its own CEO the door. Novo Nordisk announced Friday that Lars Fruergaard Jorgensen ...

Sales of the weight-loss drug created boom times for Novo Nordisk. In 2023, the company’s extraordinary success prompted the Danish central bank to keep interest rates lower than it otherwise would.